Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner discussing trends from the 2026 ASCO Meeting and its role in the evolving ADC 2.0 landscape.
Topics include KRAS-driven cancers, limitations of existing ADC payloads, Akari’s PH1 spliceosome-modulating platform, preclinical KRAS combination data, and plans for a Phase 1 trial of AKTX-101 by mid-2027.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AKTX gained 2.43% while close peers showed mixed moves (e.g., QTTB -2.64%, RNTX +0.99%, LIXT -4.48%), and only one biotech (PPCB, +13.15%) appeared on the momentum scanner, suggesting today’s action is stock-specific rather than a sector-wide ADC move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 28 | Investor commentary | Positive | +38.5% | Virtual segment explained AKTX-101 potential and ASCO abstract acceptance. |
| May 21 | Preclinical data | Positive | +255.4% | Reported synergistic preclinical activity for AKTX-101 with KRAS inhibition. |
| May 21 | Private placement | Negative | +49.9% | Announced $5.5M private placement with new ADSs and warrants. |
| May 18 | Conference appearance | Positive | +0.3% | Planned presentation on PH1 platform and AKTX-101 at healthcare showcase. |
| May 12 | Patent grant | Positive | -40.6% | Secured key European patent strengthening PH1 RNA splicing payload IP. |
Recent AKTX news linked to AKTX-101, preclinical data and financings has often produced large upside moves, with one notable negative reaction to an IP-strengthening patent announcement.
Over the last month, Akari has repeatedly highlighted its PH1 spliceosome‑modulating ADC platform and lead candidate AKTX‑101. Positive preclinical synergy data with KRAS inhibitors on May 21 and a follow‑up investor segment on May 28 were followed by strong price gains of 255.45% and 38.46%, respectively. A $5.5M private placement on May 21 also coincided with a 49.85% rise. In contrast, a European patent win on May 12 saw a -40.58% move, showing that even strategically positive IP news has not always been rewarded.
Regulatory & Risk Context
Akari has an active, effective Form S-3 shelf registration filed on July 29, 2025, with at least two prior takedowns via Form 424B5, providing established flexibility to raise additional capital as needed.
Market Pulse Summary
This announcement reinforces Akari’s positioning in the emerging “ADC 2.0” landscape, emphasizing its proprietary PH1 spliceosome‑modulating payload platform and preclinical synergy in KRAS‑mutated pancreatic cancer. It reiterates a planned first‑in‑human Phase 1 trial for AKTX‑101 by mid‑2027 and anticipated milestones through 2026. Against a backdrop of recent financings, going‑concern language, and active registration tools, investors may focus on execution toward that Phase 1 start and additional preclinical data quality.
Key Terms
antibody drug conjugates medical
adcs medical
rna splicing medical
spliceosome-modulating medical
kras medical
payload technical
phase 1 medical
first-in-human medical
AI-generated analysis. Not financial advice.
Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential
Access the Akari CEO Corner here
TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and Akari’s positioning within the evolving ADC landscape.
In the segment, Mr. Gaslightwala reflects on the accelerating pace of innovation across oncology and the growing industry focus on difficult-to-treat, genetically defined cancers, particularly KRAS-driven tumors such as pancreatic, lung and colon cancers where significant unmet need remains today.
Mr. Gaslightwala also discusses the continued momentum surrounding ADC development and what he believes represents the industry’s transition toward “ADC 2.0,” driven by increasing demand for differentiated payload technologies capable of overcoming limitations associated with existing Top1 and MMAE payload classes.
The discussion highlights emerging clinical data presented at ASCO suggesting limited efficacy when patients receive sequential ADC therapies utilizing the same payload class following relapse, reinforcing the growing need for novel payload approaches across the ADC landscape.
As part of the CEO Corner, Mr. Gaslightwala discusses Akari’s proprietary PH1 spliceosome-modulating payload platform and why the Company believes its differentiated mechanism may potentially help address resistance challenges observed with current ADC approaches while expanding therapeutic applicability across multiple difficult-to-treat solid tumors.
The segment also highlights Akari’s first accepted ASCO abstract featuring preclinical data demonstrating combination synergy between the PH1 ADC payload and a KRAS inhibitor in KRAS-mutated pancreatic cancer models, further supporting the potential applicability of Akari’s novel payload platform within the rapidly evolving KRAS therapy landscape.
In addition, Mr. Gaslightwala outlined several anticipated milestones investors should monitor throughout the remainder of 2026, including continued advancement of Akari’s PH1 spliceosome-modulating payload platform and the Company’s planned initiation of its Phase 1 first-in-human clinical trial for its lead development candidate AKTX-101which is expected by mid-2027.
The CEO Corner segment is now available here.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of a filing of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
